Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer
Molecules · 2023
DOI: 10.3390/molecules28073147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Rui Chang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China. Hauptthemen laut MEDLINE: Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Youth Innovative Science and Technology Program of Shandong Colleges and University, Shandong Natural Science Foundation, The Open Project of Shandong Collaborative Innovation Center for Antibody Drugs.
Abstract (Originalsprache)
Antitumor immunity is an essential component of cancer therapy and is primarily mediated by the innate immune response, which plays a critical role in initiating and shaping the adaptive immune response. Emerging evidence has identified innate immune checkpoints and pattern recognition receptors, such as CD47 and Toll-like receptor 7 (TLR7), as promising therapeutic targets for cancer treatment. Based on the fusion protein Fc-CV1, which comprises a high-affinity SIRPα variant (CV1), and the Fc fragment of the human IgG1 antibody, we exploited a preparation which coupled Fc-CV1 to imiquimod (TLR7 agonist)-loaded liposomes (CILPs) to actively target CT26. WT syngeneic colon tumor models. In vitro studies revealed that CILPs exhibited superior sustained release properties and cell uptake efficiency compared to free imiquimod. In vivo assays proved that CILPs exhibited more efficient accumulation in tumors, and a more significant tumor suppression effect than the control groups. This immunotherapy preparation possessed the advantages of low doses and low toxicity. These results demonstrated that a combination of immune checkpoint blockade (ICB) therapy and innate immunity agonists, such as the Fc-CV1 and imiquimod-loaded liposome preparation utilized in this study, could represent a highly effective strategy for tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China.
ORCID-Profile: Hui Yan
Förderung
- Youth Innovative Science and Technology Program of Shandong Colleges and University
- Shandong Natural Science Foundation
- The Open Project of Shandong Collaborative Innovation Center for Antibody Drugs
- Shandong Province Postgraduate Education Quality Improvement Plan
- Shandong Collaborative Innovation Center for Antibody Drugs
Zitieren
APA
Chang, R., Chu, X., Zhang, J., Fu, R., Feng, C., Jia, D., Wang, R., Yan, H., Li, G., & Li, J. (2023). Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer. Molecules. https://doi.org/10.3390/molecules28073147
Vancouver
Chang R, Chu X, Zhang J, Fu R, Feng C, Jia D, et al. Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer. Molecules. 2023. doi:10.3390/molecules28073147
BibTeX
@article{Chang2023,
author = {Chang, Rui and Chu, Xiaohong and Zhang, Jibing and Fu, Rongrong and Feng, Changshun and Jia, Dianlong and Wang, Rui and Yan, Hui and Li, Guangyong and Li, Jun},
title = {Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28073147}
}
EUVIMED